Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

• Status: Terminated
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia in this study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chulalongkorn University
• Treatments: Cyclophosphamide; Cyclosporine; Cyclosporins; Epoetin Alfa; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mycophenolate mofetil; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Age more than 18 years old

• CKD patient with anti-r-huEpo associated PRCA

Exclusion Criteria:

• Pregnancy or lactating women

• Receiving immunosuppression

• Active infection

• Previous history of allergic reaction to cyclosporine, mycophenolate mofetil, cyclophosphamide, prednisolone